Cite
MLA Citation
Janet E Brown et al.. “Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.” Lancet oncology, vol. 24, no. 3, 2023, pp. 213–227. http://access.bl.uk/ark:/81055/vdc_100179404938.0x000028